Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113


Unfavorable functional outcome is expected for elderly patients suffering from acute subdural hematoma even when presenting with preserved level of consciousness.

Sufaro Y, Avraham E, Alguyn F, Azriel A, Melamed I.

J Clin Neurosci. 2019 Jun 28. pii: S0967-5868(18)32037-X. doi: 10.1016/j.jocn.2019.05.015. [Epub ahead of print]


Early life stress induces submissive behavior in adult rats.

Frank D, Zlotnik A, Kofman O, Grinshpun J, Severynovska O, Brotfain E, Kut R, Natanel D, Melamed I, Boyko M.

Behav Brain Res. 2019 Jun 26;372:112025. doi: 10.1016/j.bbr.2019.112025. [Epub ahead of print]


A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats.

Kuts R, Melamed I, Shiyntum HN, Frank D, Grinshpun J, Zlotnik A, Brotfain E, Dubilet M, Natanel D, Boyko M.

J Vis Exp. 2019 May 22;(147). doi: 10.3791/58875.


An Alternative Model of Laser-Induced Stroke in the Motor Cortex of Rats.

Boyko M, Kuts R, Gruenbaum BF, Tsenter P, Grinshpun J, Frank D, Zvenigorodsky V, Melamed I, Brotfain E, Zlotnik A.

Biol Proced Online. 2019 May 16;21:9. doi: 10.1186/s12575-019-0097-x. eCollection 2019.


Establishment of novel technical methods for evaluating brain edema and lesion volume in stroked rats: A standardization of measurement procedures.

Boyko M, Zvenigorodsky V, Grinshpun J, Shiyntum HN, Melamed I, Kutz R, Shelef I, Brotfain E, Frank D, Zlotnik A.

Brain Res. 2019 Sep 1;1718:12-21. doi: 10.1016/j.brainres.2019.04.022. Epub 2019 Apr 23.


Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.

Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J.

Front Immunol. 2019 Feb 4;10:40. doi: 10.3389/fimmu.2019.00040. eCollection 2019.


Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.

Ochs HD, Melamed I, Borte M, Moy JN, Pyringer B, D Kobayashi AL, Knutsen AP, Smits W, Pituch-Noworolska A, Kobayashi RH.

Immunotherapy. 2018 Oct;10(14):1193-1202. doi: 10.2217/imt-2018-0074. Epub 2018 Aug 8.


Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.

Melamed IR, Borte M, Trawnicek L, Kobayashi AL, Kobayashi RH, Knutsen A, Gupta S, Smits W, Pituch-Noworolska A, Strach M, Pulka G, Ochs HD, Moy JN.

Eur J Pharm Sci. 2018 Jun 15;118:80-86. doi: 10.1016/j.ejps.2018.03.007. Epub 2018 Mar 6.


A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.

Melamed IR, Heffron M, Testori A, Lipe K.

Autism Res. 2018 Mar;11(3):421-433. doi: 10.1002/aur.1906. Epub 2018 Feb 10.


A multidisciplinary approach for the treatment of young patients with suprasellar osteochondroma.

Zanotti MC, Melamed I, Diomin V, Walter E, Baraf L, Frenkel M, Shelef I.

Childs Nerv Syst. 2018 Mar;34(3):559-563. doi: 10.1007/s00381-017-3619-3. Epub 2017 Oct 24.


Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".

Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L.

J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5. No abstract available.


Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.

Borte M, Melamed IR, Pulka G, Pyringer B, Knutsen AP, Ochs HD, Kobayashi RH, Kobayashi AL, Gupta S, Strach M, Smits W, Pituch-Noworolska A, Moy JN.

J Clin Immunol. 2017 Aug;37(6):603-612. doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29.


[An ethics call to include pregnant women in research: Reflections from the Global Forum on Bioethics in Research].

Saenz C, Alger J, Beca JP, Belizán JM, Cafferata ML, Guzmán JAC, Candanedo P JE, Duque L, Figueroa L, Garcés A, Gresh L, Gubert IC, Guilhem D, Guz G, Kaltwasser G, Lescano AR, Luna F, Cardelli AAM, Mastroleo I, Melamed IN, Del Carpio Toia AM, Palacios R, Palma GI, Salas SP, Sandoval X, de Siqueira SS, Vásquez H, de Vega BMV.

Rev Panam Salud Publica. 2017;41. pii: e13. Epub 2017 Feb 8. Spanish. No abstract available.


Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman RL, Melamed IR, Stein MR, Jolles S, Norton M, Moy JN; GMX07 Study Group.

J Clin Immunol. 2017 Aug;37(6):613. doi: 10.1007/s10875-017-0418-2. No abstract available.


Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman RL, Melamed IR, Stein MR, Jolles S, Norton M, Moy JN; GMX07 Study Group.

J Clin Immunol. 2017 Apr;37(3):301-310. doi: 10.1007/s10875-017-0383-9. Epub 2017 Mar 18. Erratum in: J Clin Immunol. 2017 Jul 17;:.


Neurologic manifestations of hereditary angioedema.

Testori A, Melamed I.

Ann Allergy Asthma Immunol. 2017 Jan;118(1):119-120. doi: 10.1016/j.anai.2016.10.016. No abstract available. Erratum in: Ann Allergy Asthma Immunol. 2017 Apr;118(4):527.


Attention Deficit Disorder and Allergic Rhinitis: Are They Related?

Melamed I, Heffron M.

J Immunol Res. 2016;2016:1596828. Epub 2016 Oct 31.


Diagnosing necrotic meningioma: a distinctive imaging pattern in diffusion MRI and MR spectroscopy.

Ben-Arie G, Serlin Y, Ivens S, Benifla M, Cagnano E, Melamed I, Merkin V, Shelef I.

Neuroradiol J. 2017 Feb;30(1):57-61. doi: 10.1177/1971400916678241. Epub 2016 Nov 19.


Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.

Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L.

J Clin Immunol. 2016 Oct;36(7):700-12. doi: 10.1007/s10875-016-0327-9. Epub 2016 Aug 31.


Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.

Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, Sharkhawy M, Engl W, Leibl H, Gelmont D, Yel L.

Immunotherapy. 2016 Oct;8(10):1175-86. doi: 10.2217/imt-2016-0066. Epub 2016 Jul 28.


Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.

Heimall J, Chen J, Church JA, Griffin R, Melamed I, Kleiner GI.

J Clin Immunol. 2016 Aug;36(6):600-9. doi: 10.1007/s10875-016-0311-4. Epub 2016 Jun 25.


Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.

Wasserman RL, Lumry W, Harris J 3rd, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi AL, Du W, Kobayashi R.

J Clin Immunol. 2016 Aug;36(6):590-9. doi: 10.1007/s10875-016-0308-z. Epub 2016 Jun 20.


Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.

Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D.

J Clin Immunol. 2016 Aug;36(6):571-82. doi: 10.1007/s10875-016-0298-x. Epub 2016 May 25.


Beyond Bioethics: A Child Rights-Based Approach to Complex Medical Decision-Making.

Wade K, Melamed I, Goldhagen J.

Perspect Biol Med. 2016;58(3):332-40. doi: 10.1353/pbm.2016.0009.


The Potential Value of the U.N. Convention on the Rights of the Child in Pediatric Bioethics Settings.

Silva MD, Lew CD, Lundy L, Lang KR, Melamed I, Shaul RZ.

Perspect Biol Med. 2016;58(3):290-305. doi: 10.1353/pbm.2016.0012.


Dural sinus obstruction following head injury: a diagnostic and clinical study.

Benifla M, Yoel U, Melamed I, Merkin V, Cohen A, Shelef I.

J Neurosurg Pediatr. 2016 Sep;18(3):253-62. doi: 10.3171/2016.3.PEDS15690. Epub 2016 May 6.


Free craniotomy versus osteoplastic craniotomy, assessment of flap viability using 99mTC MDP SPECT.

Shelef I, Golan H, Merkin V, Melamed I, Benifla M.

J Clin Neurosci. 2016 Sep;31:63-6. doi: 10.1016/j.jocn.2015.11.031. Epub 2016 Apr 8.


Supraciliary keyhole craniotomy for anterior frontal lesions in children.

Benifla M, Merkin V, Rosenthal G, Shoshan Y, Melamed I.

J Clin Neurosci. 2016 Apr;26:37-41. doi: 10.1016/j.jocn.2015.10.024. Epub 2016 Jan 4.


Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.

Melamed IR, Gupta S, Stratford Bobbitt M, Hyland N, Moy JN.

Clin Exp Immunol. 2016 May;184(2):228-36. doi: 10.1111/cei.12760. Epub 2016 Feb 15.


A new subset of common variable immune deficiency characterized by reduced C1 esterase inhibitor levels.

Melamed IR, Heffron M, McGee S, Ulltate Sanz L, Testori A.

Ann Allergy Asthma Immunol. 2015 Jul;115(1):83-4. doi: 10.1016/j.anai.2015.04.023. No abstract available.


Mast cells, brain inflammation and autism.

Theoharides TC, Stewart JM, Panagiotidou S, Melamed I.

Eur J Pharmacol. 2016 May 5;778:96-102. doi: 10.1016/j.ejphar.2015.03.086. Epub 2015 May 1. Review.


Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.

Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug.


X-microstenting and transmesh coiling in the management of wide-necked tent-like anterior communicating artery aneurysms.

Cohen JE, Melamed I, Itshayek E.

J Clin Neurosci. 2014 Apr;21(4):664-7. doi: 10.1016/j.jocn.2013.09.003. Epub 2013 Nov 28.


Cell-free DNA as a potential marker to predict carbon tetrachloride-induced acute liver injury in rats.

Gruenbaum BF, Boyko M, Delgado B, Douvdevany A, Gruenbaum SE, Melamed I, Gideon M, Cesnulis E, Shapira Y, Zlotnik A.

Hepatol Int. 2013 Jun;7(2):721-7. doi: 10.1007/s12072-012-9414-z. Epub 2012 Nov 22.


Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F.

Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31.


The role of hypothermia in the regulation of blood glutamate levels in naive rats.

Boyko M, Kuts R, Gruenbaum BF, Melamed I, Gruenbaum SE, Klein M, Shapira Y, Zlotnik A.

J Neurosurg Anesthesiol. 2013 Apr;25(2):174-83. doi: 10.1097/ANA.0b013e31827ee0ac.


Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.

Melamed I, Testori A, Spirer Z.

Int Rev Immunol. 2012 Dec;31(6):451-61. doi: 10.3109/08830185.2012.732631. Review.


The neuro-behavioral profile in rats after subarachnoid hemorrhage.

Boyko M, Azab AN, Kuts R, Gruenbaum BF, Gruenbaum SE, Melamed I, Brotfain E, Shapira Y, Cesnulis E, Zlotnik A.

Brain Res. 2013 Jan 23;1491:109-16. doi: 10.1016/j.brainres.2012.10.061. Epub 2012 Nov 2.


Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naïve rats.

Boyko M, Stepensky D, Gruenbaum BF, Gruenbaum SE, Melamed I, Ohayon S, Glazer M, Shapira Y, Zlotnik A.

Neurochem Res. 2012 Oct;37(10):2198-205. doi: 10.1007/s11064-012-0843-9. Epub 2012 Jul 31.


Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 Study Group.

J Allergy Clin Immunol. 2012 Oct;130(4):951-7.e11. doi: 10.1016/j.jaci.2012.06.021. Epub 2012 Jul 28.


The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage.

Boyko M, Melamed I, Gruenbaum BF, Gruenbaum SE, Ohayon S, Leibowitz A, Brotfain E, Shapira Y, Zlotnik A.

Neurotherapeutics. 2012 Jul;9(3):649-57. doi: 10.1007/s13311-012-0129-6.


Novel use of an exchange catheter to facilitate intubation with an Aintree catheter in a tall patient with a predicted difficult airway: a case report.

Gruenbaum SE, Gruenbaum BF, Tsaregorodtsev S, Dubilet M, Melamed I, Zlotnik A.

J Med Case Rep. 2012 Apr 13;6:108. doi: 10.1186/1752-1947-6-108.


Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM.

J Clin Immunol. 2012 Aug;32(4):663-9. doi: 10.1007/s10875-012-9656-5. Epub 2012 Mar 6.


Cell-free DNA as a marker for prediction of brain damage in traumatic brain injury in rats.

Ohayon S, Boyko M, Saad A, Douvdevani A, Gruenbaum BF, Melamed I, Shapira Y, Teichberg VI, Zlotnik A.

J Neurotrauma. 2012 Jan 20;29(2):261-7. doi: 10.1089/neu.2011.1938. Epub 2011 Dec 7.


Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke.

Boyko M, Zlotnik A, Gruenbaum BF, Gruenbaum SE, Ohayon S, Kuts R, Melamed I, Regev A, Shapira Y, Teichberg VI.

Eur J Neurosci. 2011 Nov;34(9):1432-41. doi: 10.1111/j.1460-9568.2011.07864.x. Epub 2011 Sep 21.


Trends over time in the management of 2253 patients with cerebral aneurysms: A single practice experience.

Payner TD, Melamed I, Ansari S, Leipzig TJ, Scott JA, Denardo AJ, Horner TG, Redelman K, Cohen-Gadol AA.

Surg Neurol Int. 2011;2:110. doi: 10.4103/2152-7806.83728. Epub 2011 Aug 13.


Cell-free DNA--a marker to predict ischemic brain damage in a rat stroke experimental model.

Boyko M, Ohayon S, Goldsmith T, Douvdevani A, Gruenbaum BF, Melamed I, Knyazer B, Shapira Y, Teichberg VI, Elir A, Klein M, Zlotnik A.

J Neurosurg Anesthesiol. 2011 Jul;23(3):222-8. doi: 10.1097/ANA.0b013e31821b536a.


Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.

Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA.

Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000.


Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.

Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, Engl W, Leibl H, Sobolevsky L, Gelmont D, Schiff RI, Grossman WJ.

J Clin Immunol. 2011 Jun;31(3):323-31. doi: 10.1007/s10875-011-9512-z. Epub 2011 Mar 22.


[Urgent removal of ruptured cerebral arteriovenous malformations in children].

Benifla M, Shelef I, Melamed I, Merkin V, Barrelly R, Cohen A.

Harefuah. 2010 Mar;149(3):148-52, 195. Hebrew.


Supplemental Content

Loading ...
Support Center